Targeted Oncologics Will Sustain High Prices With Clear Benefits, GSK Says
Executive Summary
The high price tags of targeted therapies will continue to be supported as specific populations are identified where the oncologics can show a clear benefit, according to GlaxoSmithKline Chairman of R&D Tachi Yamada
You may also be interested in...
Genetic Testing Will Contribute To Growth In Drug Spending, Medco Predicts
The growing prevalence of genetic testing as a clinical tool will drive increased drug spending and have a significant impact on medical practice, Medco predicts in its 2006 Drug Trend Report
Genetic Testing Will Contribute To Growth In Drug Spending, Medco Predicts
The growing prevalence of genetic testing as a clinical tool will drive increased drug spending and have a significant impact on medical practice, Medco predicts in its 2006 Drug Trend Report
Biotech Drugs Will Face Competitive And Reimbursement Pressure – Analysts
Increasing competition could negatively impact market potential for biotech products, Merrill Lynch's David Munno suggested